Deutsche Bank AG Raises Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Deutsche Bank AG increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 226.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 105,583 shares of the specialty pharmaceutical company's stock after purchasing an additional 73,213 shares during the quarter. Deutsche Bank AG owned approximately 0.19% of Supernus Pharmaceuticals worth $3,818,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Barclays PLC grew its stake in Supernus Pharmaceuticals by 88.3% in the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock worth $3,393,000 after purchasing an additional 51,005 shares in the last quarter. Franklin Resources Inc. lifted its holdings in Supernus Pharmaceuticals by 7.6% during the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company's stock worth $987,000 after buying an additional 2,121 shares during the period. Empowered Funds LLC purchased a new stake in Supernus Pharmaceuticals during the fourth quarter worth $1,498,000. Smartleaf Asset Management LLC lifted its holdings in Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after buying an additional 870 shares during the period. Finally, Envestnet Asset Management Inc. lifted its holdings in Supernus Pharmaceuticals by 6.2% during the fourth quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company's stock worth $2,169,000 after buying an additional 3,495 shares during the period.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock traded up $0.06 during mid-day trading on Friday, reaching $32.10. 330,988 shares of the company were exchanged, compared to its average volume of 483,726. The business has a fifty day moving average of $31.98 and a 200 day moving average of $34.74. The firm has a market cap of $1.80 billion, a P/E ratio of 30.00 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28.

Wall Street Analyst Weigh In

A number of research firms have weighed in on SUPN. Wall Street Zen upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, May 16th. Cantor Fitzgerald restated a "neutral" rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.